HomeCompareCNVVY vs MAIN

CNVVY vs MAIN: Dividend Comparison 2026

CNVVY yields 2.49% · MAIN yields 7.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNVVY wins by $123.66M in total portfolio value· pulled ahead in Year 9
10 years
CNVVY
CNVVY
● Live price
2.49%
Share price
$11.64
Annual div
$0.29
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$171.61M
Annual income
$159,331,380.90
Full CNVVY calculator →
MAIN
Main Street Capital Corporation
● Live price
7.09%
Share price
$51.65
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.95M
Annual income
$40,208,699.11
Full MAIN calculator →

Portfolio growth — CNVVY vs MAIN

📍 CNVVY pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNVVYMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNVVY + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNVVY pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNVVY
Annual income on $10K today (after 15% tax)
$211.86/yr
After 10yr DRIP, annual income (after tax)
$135,431,673.77/yr
MAIN
Annual income on $10K today (after 15% tax)
$602.32/yr
After 10yr DRIP, annual income (after tax)
$34,177,394.24/yr
At 15% tax rate, CNVVY beats the other by $101,254,279.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNVVY + MAIN for your $10,000?

CNVVY: 50%MAIN: 50%
100% MAIN50/50100% CNVVY
Portfolio after 10yr
$109.78M
Annual income
$99,770,040.01/yr
Blended yield
90.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

CNVVY
No analyst data
Altman Z
4.0
Piotroski
7/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+26.3% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNVVY buys
0
MAIN buys
0
No recent congressional trades found for CNVVY or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNVVYMAIN
Forward yield2.49%7.09%
Annual dividend / share$0.29$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%72.7%
Portfolio after 10y$171.61M$47.95M
Annual income after 10y$159,331,380.90$40,208,699.11
Total dividends collected$170.67M$46.82M
Payment frequencyquarterlymonthly
SectorStockBDC

Year-by-year: CNVVY vs MAIN ($10,000, DRIP)

YearCNVVY PortfolioCNVVY Income/yrMAIN PortfolioMAIN Income/yrGap
1$11,198$498.50$12,464$1,223.78$1.3KMAIN
2$13,026$1,043.44$16,353$2,343.58$3.3KMAIN
3$16,206$2,268.61$23,105$4,724.42$6.9KMAIN
4$22,616$5,275.73$36,226$10,256.23$13.6KMAIN
5$37,961$13,761.64$65,426$24,707.64$27.5KMAIN
6$83,794$43,175.04$142,101$68,562.02$58.3KMAIN
7$267,794$178,135.05$388,521$228,799.95$120.7KMAIN
8$1,350,649$1,064,109.17$1,397,868$961,169.80$47.2KMAIN
9← crossover$11,476,878$10,031,683.35$6,884,663$5,313,459.69+$4.59MCNVVY
10$171,611,640$159,331,380.90$47,947,060$40,208,699.11+$123.66MCNVVY

CNVVY vs MAIN: Complete Analysis 2026

CNVVYStock

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.

Full CNVVY Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this CNVVY vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNVVY vs SCHDCNVVY vs JEPICNVVY vs OCNVVY vs KOCNVVY vs ARCCCNVVY vs HTGCCNVVY vs GBDCCNVVY vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.